RAPTRAPT Therapeutics, Inc.

$959M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$314,000

Operating Income

-$33M

Net Income

-$31M

EPS (Diluted)

$-6.32

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$156M

Total Liabilities

$25M

Stockholders' Equity

$131M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$314,000	$0	—
Operating Income	-$33M	-$32M	-3.0%
Net Income	-$31M	-$29M	-4.3%

RAPT Q1 2024 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena